#StayHappening
Thu Nov 05 2026 at 05:00 pm to 07:00 pm UTC-08:00

Targeting RAS-Addicted Cancers with RAS(ON) Tri-Complex Inhibitors

  • The Alexandria at San Carlos · San Carlos
  • From USD 40.00
BioScience Forum Publisher / Host BioScience Forum
Share
Targeting RAS-Addicted Cancers with RAS(ON) Tri-Complex Inhibitors
Advertisement
Hear how Revolution Medicines has built a portfolio of novel inhibitors that are tailored to bind to different RAS(ON) proteins.
About this Event

Targeting RAS-Addicted Cancers with RAS(ON) Tri-Complex Inhibitors
* * * * *

RAS is a molecular switch that toggles between an inactive GDP bound (OFF) state and an active GTP-bound (ON) state. Accumulation of RAS(ON) in tumor cells drives uncontrolled RAS pathway activation and growth in RAS mutant cancers. RAS(ON) proteins have been amongst the most notoriously undruggable targets in cancer due in large part to their typically smooth, featureless surface. The tri-complex platform is inspired by one of nature’s solutions to modulating complex cellular targets. Tri-complex inhibitors bind to the chaperone protein cyclophilin A to create a novel interface with high affinity for RAS(ON) proteins. Using structure-guided design, the resulting inhibitory tri-complexes can be tailored to bind to different RAS(ON) proteins, including those with oncogenic mutations at each of the three most commonly mutated hotspots - G12, G13 and Q61. Using this approach, Revolution Medicines has built a portfolio of novel RAS(ON) inhibitors, with diverse and complementary selectivity profiles, all targeting the active state of RAS.
Daraxonrasib is an oral, RAS(ON) multi-selective, tri-complex inhibitor designed to target cancers driven by multiple common RAS genotypes. RASONQUE (daraxonrasib) received FDA approval in August 2026 for the treatment of adults with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Dr. Smith will describe the preclinical and clinical development of daraxonrasib and related RAS(ON) tri-complex inhibitors in the pipeline at Revolution Medicines for RAS-driven cancers.


Agenda

🕑: 05:00 PM - 06:00 PM
Networking, Appetizers and Drinks

Info: Network with local bioscience professionals while enjoying appetizers and drinks.


🕑: 06:00 PM - 07:00 PM
Presentation

Info: Scientific presentation by distinguished guest speaker followed by a lively Q&A.


Advertisement

Event venue & nearby stays

The Alexandria at San Carlos, 835 Industrial Road, San Carlos, United States

Tickets USD 40.00 to USD 45.00
Concerts, fests, parties, meetups — all the happenings, one place.

Discover more events by tag

Ask AI if this event suits you

Keep the plans coming

More events in San Carlos

San Carlos is happening.

See everything else that’s on — concerts, markets, comedy and more.